Skip to Main Content

Paper Details

Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.
Blood Cancer Discov
60
2021
-, ABL1, ALL, B, B-ALL, BCR, DUX4, DUX4-, DUX4-rearranged B, DUX4-rearranged B-ALL, ETP, ETV6, KMT2A, KMT2A-rearranged ALL, MEF2D, PAX5alt, PBX1, RUNX1, T, T-ALL, T-cell, TCF3, ZNF384, acute lymphoblastic leukemia, children, high-hyperdiploid, hypodiploid ALL, iAMP21, patients
Author NameAffiliation
Sima JehaSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Sima JehaSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Kathryn G RobertsSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Chunxu QuSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Cheng ChengSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Ching-Hon PuiDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Charles G MullighanSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Ching-Hon PuiSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Ching-Hon PuiSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
Ching-Hon PuiSt. Jude Children's Research Hospital and the University of Tennessee Health Science Center
  • 1 - 11

Datasets

Release 1.2